MEDISTIM ASA (MEDI.OL) Stock Fundamental Analysis
OSL:MEDI - Euronext Oslo - NO0010159684 - Common Stock - Currency: NOK
We assign a fundamental rating of 6 out of 10 to MEDI. MEDI was compared to 53 industry peers in the Health Care Equipment & Supplies industry. MEDI gets an excellent profitability rating and is at the same time showing great financial health properties. MEDI has a decent growth rate and is not valued too expensively. These ratings could make MEDI a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
MEDI had positive earnings in the past year.
In the past year MEDI had a positive cash flow from operations.
Each year in the past 5 years MEDI has been profitable.
In the past 5 years MEDI always reported a positive cash flow from operatings.
1.2 Ratios
MEDI has a Return On Assets of 18.06%. This is amongst the best in the industry. MEDI outperforms 94.34% of its industry peers.
MEDI has a better Return On Equity (23.78%) than 90.57% of its industry peers.
MEDI has a better Return On Invested Capital (21.60%) than 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MEDI is significantly above the industry average of 8.33%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.06% | ||
| ROE | 23.78% | ||
| ROIC | 21.6% |
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
1.3 Margins
The Profit Margin of MEDI (18.46%) is better than 86.79% of its industry peers.
MEDI's Profit Margin has been stable in the last couple of years.
MEDI has a better Operating Margin (23.30%) than 92.45% of its industry peers.
In the last couple of years the Operating Margin of MEDI has remained more or less at the same level.
MEDI's Gross Margin of 79.79% is amongst the best of the industry. MEDI outperforms 88.68% of its industry peers.
MEDI's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.3% | ||
| PM (TTM) | 18.46% | ||
| GM | 79.79% |
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDI is creating value.
MEDI has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for MEDI has been increased compared to 5 years ago.
Compared to 1 year ago, MEDI has a worse debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of MEDI is 0.21, which is an excellent value as it means it would take MEDI, only 0.21 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MEDI (0.21) is better than 96.23% of its industry peers.
MEDI has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
MEDI has a Debt to Equity ratio of 0.06. This is amongst the best in the industry. MEDI outperforms 92.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.21 | ||
| Altman-Z | N/A |
ROIC/WACC2.51
WACC8.62%
2.3 Liquidity
A Current Ratio of 4.00 indicates that MEDI has no problem at all paying its short term obligations.
The Current ratio of MEDI (4.00) is better than 84.91% of its industry peers.
MEDI has a Quick Ratio of 2.50. This indicates that MEDI is financially healthy and has no problem in meeting its short term obligations.
MEDI has a better Quick ratio (2.50) than 81.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4 | ||
| Quick Ratio | 2.5 |
3. Growth
3.1 Past
MEDI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.06%.
The Earnings Per Share has been growing by 12.58% on average over the past years. This is quite good.
MEDI shows a small growth in Revenue. In the last year, the Revenue has grown by 6.88%.
The Revenue has been growing by 10.06% on average over the past years. This is quite good.
EPS 1Y (TTM)-0.06%
EPS 3Y14.25%
EPS 5Y12.58%
EPS Q2Q%11.54%
Revenue 1Y (TTM)6.88%
Revenue growth 3Y13.17%
Revenue growth 5Y10.06%
Sales Q2Q%11.44%
3.2 Future
Based on estimates for the next years, MEDI will show a small growth in Earnings Per Share. The EPS will grow by 6.40% on average per year.
Based on estimates for the next years, MEDI will show a quite strong growth in Revenue. The Revenue will grow by 8.86% on average per year.
EPS Next Y7.04%
EPS Next 2Y1.53%
EPS Next 3Y3.37%
EPS Next 5Y6.4%
Revenue Next Year8.3%
Revenue Next 2Y6.53%
Revenue Next 3Y7.69%
Revenue Next 5Y8.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 28.22 indicates a quite expensive valuation of MEDI.
Based on the Price/Earnings ratio, MEDI is valued a bit cheaper than the industry average as 75.47% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.79. MEDI is around the same levels.
MEDI is valuated quite expensively with a Price/Forward Earnings ratio of 27.38.
MEDI's Price/Forward Earnings ratio is in line with the industry average.
MEDI's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 21.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.22 | ||
| Fwd PE | 27.38 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MEDI is valued a bit cheaper than 67.92% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDI indicates a somewhat cheap valuation: MEDI is cheaper than 77.36% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.78 | ||
| EV/EBITDA | 18.34 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDI does not grow enough to justify the current Price/Earnings ratio.
MEDI has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.01
PEG (5Y)2.24
EPS Next 2Y1.53%
EPS Next 3Y3.37%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.68%, MEDI has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.45, MEDI pays a better dividend. On top of this MEDI pays more dividend than 94.34% of the companies listed in the same industry.
MEDI's Dividend Yield is a higher than the S&P500 average which is at 2.51.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.68% |
5.2 History
On average, the dividend of MEDI grows each year by 14.87%, which is quite nice.
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
79.37% of the earnings are spent on dividend by MEDI. This is not a sustainable payout ratio.
The dividend of MEDI is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP79.37%
EPS Next 2Y1.53%
EPS Next 3Y3.37%
OSL:MEDI (4/25/2025, 7:00:00 PM)
160
-3 (-1.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners60.75%
Inst Owner ChangeN/A
Ins Owners2.83%
Ins Owner ChangeN/A
Market Cap2.93B
Analysts42.22
Price Target175.44 (9.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.68% |
Yearly Dividend4.5
Dividend Growth(5Y)14.87%
DP79.37%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.77%
Min EPS beat(2)-21.02%
Max EPS beat(2)-18.51%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.33%
Min Revenue beat(2)-4.3%
Max Revenue beat(2)8.95%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.5%
EPS NY rev (3m)-4.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.22 | ||
| Fwd PE | 27.38 | ||
| P/S | 5.22 | ||
| P/FCF | 24.78 | ||
| P/OCF | 20.51 | ||
| P/B | 6.72 | ||
| P/tB | 6.72 | ||
| EV/EBITDA | 18.34 |
EPS(TTM)5.67
EY3.54%
EPS(NY)5.84
Fwd EY3.65%
FCF(TTM)6.46
FCFY4.04%
OCF(TTM)7.8
OCFY4.88%
SpS30.68
BVpS23.81
TBVpS23.81
PEG (NY)4.01
PEG (5Y)2.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.06% | ||
| ROE | 23.78% | ||
| ROCE | 28.03% | ||
| ROIC | 21.6% | ||
| ROICexc | 35.03% | ||
| ROICexgc | 35.03% | ||
| OM | 23.3% | ||
| PM (TTM) | 18.46% | ||
| GM | 79.79% | ||
| FCFM | 21.05% |
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
ROICexc(3y)39.99%
ROICexc(5y)39.99%
ROICexgc(3y)48.52%
ROICexgc(5y)48.01%
ROCE(3y)32.29%
ROCE(5y)33.19%
ROICexcg growth 3Y-6.52%
ROICexcg growth 5Y0.36%
ROICexc growth 3Y-8.47%
ROICexc growth 5Y0.04%
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
F-Score4
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.21 | ||
| Debt/EBITDA | 0.16 | ||
| Cap/Depr | 100.75% | ||
| Cap/Sales | 4.39% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.98% | ||
| Profit Quality | 114.04% | ||
| Current Ratio | 4 | ||
| Quick Ratio | 2.5 | ||
| Altman-Z | N/A |
F-Score4
WACC8.62%
ROIC/WACC2.51
Cap/Depr(3y)105.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.78%
Cap/Sales(5y)N/A
Profit Quality(3y)91.83%
Profit Quality(5y)103.03%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.06%
EPS 3Y14.25%
EPS 5Y12.58%
EPS Q2Q%11.54%
EPS Next Y7.04%
EPS Next 2Y1.53%
EPS Next 3Y3.37%
EPS Next 5Y6.4%
Revenue 1Y (TTM)6.88%
Revenue growth 3Y13.17%
Revenue growth 5Y10.06%
Sales Q2Q%11.44%
Revenue Next Year8.3%
Revenue Next 2Y6.53%
Revenue Next 3Y7.69%
Revenue Next 5Y8.86%
EBIT growth 1Y-0.28%
EBIT growth 3Y4.07%
EBIT growth 5Y7.86%
EBIT Next Year10%
EBIT Next 3Y10.15%
EBIT Next 5YN/A
FCF growth 1Y41.87%
FCF growth 3Y-0.65%
FCF growth 5Y12.16%
OCF growth 1Y26.43%
OCF growth 3Y3.75%
OCF growth 5Y12.23%